CA2546189A1 - Inhibitors of the mutant form of kit - Google Patents
Inhibitors of the mutant form of kit Download PDFInfo
- Publication number
- CA2546189A1 CA2546189A1 CA002546189A CA2546189A CA2546189A1 CA 2546189 A1 CA2546189 A1 CA 2546189A1 CA 002546189 A CA002546189 A CA 002546189A CA 2546189 A CA2546189 A CA 2546189A CA 2546189 A1 CA2546189 A1 CA 2546189A1
- Authority
- CA
- Canada
- Prior art keywords
- kit
- del
- inhibitor
- mutant form
- midostaurin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/44—Multiple drug resistance
Abstract
The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered.
Description
Inhibitors of the mutant form of KIT
The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT is administered.
The c-kit gene encodes a receptor protein tyrosine kinase, which is herein referred to as KIT, but which is also known as mast/stem cell growth factor receptor. The amino acid sequence of KIT and the nucleotide sequence of the c-kit gene are known. See Swiss Prot.: P10721. Upon binding its ligand, stem cell factor, KIT forms a dimer that is autophosphorylated and activates signaling cascades that lead to cell growth.
Mutations that lead to an activated form of KIT, especially forms that are activated independently of its ligand, are known and are believed to play a role in certain proliferative diseases, such as mast cell diseases, like mastocytosis, particularly systemic mastocytosis, acute myelogenous leukemia, gastrointestinal stromal tumors, sinonasal NK/T-cell lymphoma, seminomas and dysgerminomas.
Imatinib, which is marketed as its mesylate salt under the brandname GLIVEC or GLEEVEC, is known to inhibit wild type KIT and certain KIT mutations e.g.
those in exons commonly found in gastrointestinal stromal tumors (GIST). However, it is also inactive or significantly less active against certain other mutant forms of KIT, for example the D816V
mutation commonly found in systemic mastocytosis. The present invention is based upon research that correlates the treatment of a disease characterized by a mutant form of KIT
with an appropriate alternative pharmaceutical therapy based on the alternative's ability to inhibit the mutant KIT.
Thus, the present invention relates to a method of treating a KIT dependent disease in a patient, which comprises (a) identifying the mutant form of KIT associated with the KIT dependent disease;
and (b) administering to the patient an effective mutant KIT-inhibiting amount of an inhibitor selected from the group consisting of midostaurin, vatalanib and compound A.
KIT dependent diseases are generally proliferative diseases that are characterized by excessive KIT kinase activity due to an activating mutation in KIT. Such activating mutations are known in the art and are identified by techniques known in the art.
KIT dependent diseases include diseases characterized by the following known KIT
mutations: D816F, D816H, D816N, D816Y, D816V, K642E, Y823D, Del 550-558, Del 561, N822K, V654A, N822H, Del 550-558 + V654A, Del 557-561 + V654A, Ins503AY, V560G, 558NP, Del 557-558, Del W559-560, F522C, Del 579, R634W; K642E, T801 I, C809G, D820Y, N822K, N822H, Y823D, Y823C and T6701.
In an important embodiment of the present invention, the KIT dependent disease is resistant to treatment with imatinib. A KIT dependent disease that is resistant to imatinib is generally a KIT dependent disease as described above wherein imatinib, administered at a dose of 400-1000 mg/day, does not provide sufficient inhibition of the mutant KIT to effect a significant therapeutic benefit. Generally, mutant KIT that is resistant to imatinib has an in vitro ICSO of the mutant KIT greater than about 3 micromolar. Imatinib resistant KIT
mutations include D816F, D816H, D816N, D816Y, D816V, T6701 and mutant forms that include V654A.
The selection of a compound that inhibits the mutant form of KIT is based on testing the compound or a number of compounds for their ability to inhibit the mutant KIT. Such testing is carried out by standard inhibition assays that are known in the art or within the skill of the artisan.
The KIT inhibitors utilized in accordance with the present method include midostaurin, vatalanib and compound A. Midostaurin (US5;093,330) and vatalanib (WO
98/35958) are known in the art. Compound A is a compound of the formula Compound A
O
N N F
I
/N / ' F
N /
And may be produced according to WO 04/005281.
Appropriate dosages of midostaurin, vatanalib and compound A are determined by routine methods.
An appropriate dose of midostaurin is administered, e.g., once, twice or three times a day, for a total dose of 25 - 300 preferably 50-300 more preferably 50 -100 most preferably 100-300 mg daily, e.g., two or three times a day, for a total dose of 150-250 mg, preferably 225 mg daily.
An appropriate daily dose of vatanalib is an amount in the range from 300-4000 mg, e.g., in the range from 300-2000 mg/day or 300-1500 mg/day, in particular, 300, 500, 750, 1000, 1250, 1500 or 2000 mg/day, particularly 1250 mg/day.
The daily dose of compound A for a 70 kg/person is from approximately 0.05-5 g, preferably from approximately 0.25-1.5 g.
EXAMPLES
The human KIT gene encoding as 544-976 was cloned into the baculovirus donor plasrnid pFB-GST-01. This coding sequence was excised using restriction endonucleases Bam H1 and EcoR1 and ligated to a Bac-to-Bac donor vector pFB-GEX-P1 with compatible ends. Subsequently the desired mutations were brought into the KIT gene by methods know to a person skilled in the art. Due to a frame shift within the original plasmid that was used to generate the mutant coding sequences, the mutated plasmid inserts were excised and inserted into the Bac-to-Bac donor vector pFB-GST-01 using the restriction enzymes BamH1-EcoR1 for each mutant shown in Figure 1. Automated sequencing confirmed the correct sequence to be present for each mutant plasmid.
Bacrnid DNA was generated from 10 colonies each of DH10Bac cells transformed with pFB-G01-KIT-mutant plasmid clones as described in materials and methods and these transfected into Sf9 cells. The transfected cells were pelleted and the resultant recombinant baculovirus present in the supernatant medium amplified. Western blotting was applied to the lysed cell pellets to confirm the expression of the GST-c-KIT fusion protein by the viral clones using anti-KIT and anti-GST antibodies for immonudetection.
The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT is administered.
The c-kit gene encodes a receptor protein tyrosine kinase, which is herein referred to as KIT, but which is also known as mast/stem cell growth factor receptor. The amino acid sequence of KIT and the nucleotide sequence of the c-kit gene are known. See Swiss Prot.: P10721. Upon binding its ligand, stem cell factor, KIT forms a dimer that is autophosphorylated and activates signaling cascades that lead to cell growth.
Mutations that lead to an activated form of KIT, especially forms that are activated independently of its ligand, are known and are believed to play a role in certain proliferative diseases, such as mast cell diseases, like mastocytosis, particularly systemic mastocytosis, acute myelogenous leukemia, gastrointestinal stromal tumors, sinonasal NK/T-cell lymphoma, seminomas and dysgerminomas.
Imatinib, which is marketed as its mesylate salt under the brandname GLIVEC or GLEEVEC, is known to inhibit wild type KIT and certain KIT mutations e.g.
those in exons commonly found in gastrointestinal stromal tumors (GIST). However, it is also inactive or significantly less active against certain other mutant forms of KIT, for example the D816V
mutation commonly found in systemic mastocytosis. The present invention is based upon research that correlates the treatment of a disease characterized by a mutant form of KIT
with an appropriate alternative pharmaceutical therapy based on the alternative's ability to inhibit the mutant KIT.
Thus, the present invention relates to a method of treating a KIT dependent disease in a patient, which comprises (a) identifying the mutant form of KIT associated with the KIT dependent disease;
and (b) administering to the patient an effective mutant KIT-inhibiting amount of an inhibitor selected from the group consisting of midostaurin, vatalanib and compound A.
KIT dependent diseases are generally proliferative diseases that are characterized by excessive KIT kinase activity due to an activating mutation in KIT. Such activating mutations are known in the art and are identified by techniques known in the art.
KIT dependent diseases include diseases characterized by the following known KIT
mutations: D816F, D816H, D816N, D816Y, D816V, K642E, Y823D, Del 550-558, Del 561, N822K, V654A, N822H, Del 550-558 + V654A, Del 557-561 + V654A, Ins503AY, V560G, 558NP, Del 557-558, Del W559-560, F522C, Del 579, R634W; K642E, T801 I, C809G, D820Y, N822K, N822H, Y823D, Y823C and T6701.
In an important embodiment of the present invention, the KIT dependent disease is resistant to treatment with imatinib. A KIT dependent disease that is resistant to imatinib is generally a KIT dependent disease as described above wherein imatinib, administered at a dose of 400-1000 mg/day, does not provide sufficient inhibition of the mutant KIT to effect a significant therapeutic benefit. Generally, mutant KIT that is resistant to imatinib has an in vitro ICSO of the mutant KIT greater than about 3 micromolar. Imatinib resistant KIT
mutations include D816F, D816H, D816N, D816Y, D816V, T6701 and mutant forms that include V654A.
The selection of a compound that inhibits the mutant form of KIT is based on testing the compound or a number of compounds for their ability to inhibit the mutant KIT. Such testing is carried out by standard inhibition assays that are known in the art or within the skill of the artisan.
The KIT inhibitors utilized in accordance with the present method include midostaurin, vatalanib and compound A. Midostaurin (US5;093,330) and vatalanib (WO
98/35958) are known in the art. Compound A is a compound of the formula Compound A
O
N N F
I
/N / ' F
N /
And may be produced according to WO 04/005281.
Appropriate dosages of midostaurin, vatanalib and compound A are determined by routine methods.
An appropriate dose of midostaurin is administered, e.g., once, twice or three times a day, for a total dose of 25 - 300 preferably 50-300 more preferably 50 -100 most preferably 100-300 mg daily, e.g., two or three times a day, for a total dose of 150-250 mg, preferably 225 mg daily.
An appropriate daily dose of vatanalib is an amount in the range from 300-4000 mg, e.g., in the range from 300-2000 mg/day or 300-1500 mg/day, in particular, 300, 500, 750, 1000, 1250, 1500 or 2000 mg/day, particularly 1250 mg/day.
The daily dose of compound A for a 70 kg/person is from approximately 0.05-5 g, preferably from approximately 0.25-1.5 g.
EXAMPLES
The human KIT gene encoding as 544-976 was cloned into the baculovirus donor plasrnid pFB-GST-01. This coding sequence was excised using restriction endonucleases Bam H1 and EcoR1 and ligated to a Bac-to-Bac donor vector pFB-GEX-P1 with compatible ends. Subsequently the desired mutations were brought into the KIT gene by methods know to a person skilled in the art. Due to a frame shift within the original plasmid that was used to generate the mutant coding sequences, the mutated plasmid inserts were excised and inserted into the Bac-to-Bac donor vector pFB-GST-01 using the restriction enzymes BamH1-EcoR1 for each mutant shown in Figure 1. Automated sequencing confirmed the correct sequence to be present for each mutant plasmid.
Bacrnid DNA was generated from 10 colonies each of DH10Bac cells transformed with pFB-G01-KIT-mutant plasmid clones as described in materials and methods and these transfected into Sf9 cells. The transfected cells were pelleted and the resultant recombinant baculovirus present in the supernatant medium amplified. Western blotting was applied to the lysed cell pellets to confirm the expression of the GST-c-KIT fusion protein by the viral clones using anti-KIT and anti-GST antibodies for immonudetection.
Gem R mln ('~'1 GST-0-c-KIT-v6s4A
e~ouv(msy De( 550-558 + V654A
Tn7R............_.......
F.roRt(20i11 pFB-G01-c-IfIT ,1"tt(zosyN822K
6828 by ~ sart(zo;tl %' ' De1557-561 "
__sun (zosi7 -~~~-,smit2o9."> Dej550-558 ~' ~
,'':~~
1'nti(=IGi) , D816N
'.~;
\ aa(zlztl ~.Ynoit~t:6>
' prri (2132?
' ~A
' ; D816V
t~ui(?san ;' ~ttrn~uittnss ,' Tn7L
AmpR
I ' De1557-561+V654 A
Figure 1 Vatalanib Compound A
Kit Mutation ICso (pM) (avg) ICSO (wM) (avg) D816F >10 >10 D816H >10 >10 D816N >10 <10 D816Y >10 >10 D816V >10 >10 K642E <1 <10 Y823D <1 <1 Del 550-558 <1 <2 Del 557-561 <1 <2 N822K <2 <10 V654A >10 >10 N822H <2 <10 Del 550-558 + <10 <10 Del 557-561 + >10 >10 Midostaurin average N of HIS pre aration IC50 SEM values M
HT-KtT-TA23 art 1.7 0.15 2 HT-KiT TA23 -D820t~ 0.084 0.05 2 HT-tCIT TA23 -T6701 0.89 0.21 2 average N of CAST preparation IC50 SEM values ~M
t~3T-KIT ~,tt 1.8 0.26 10 #;~ST-#~I"f Del 557-561 0.32 0.042 3 CST-f~IT Del 550-558 0.53 0.057 3 CST-ESIT l3el 550-55$x- 0.27 0.079 5 CST-IaCIT Del 557-561 0.34 0.11 5 ~- ~~aS~.A
O xT-I'IT ~'G54A 0.46 0.16 5 t,~ST-fCIT I~642E 0.64 0.036 4 ~aST-fCIT I~tG34~! 0.33 0.13 2 t~ST-~fi#T T6701 + ~e1 0.11 0.05 2 ~ST-~GIT' t581t~P 0.41 0.055 5 SST-I'CIT D816H 0.35 0.078 5 GST-I~CIT D816~1 0.74 0.25 5 ~'aST-i~IT i~Sl6Y 0.29 0.11 9 SST-k~IT #~816'~T 0.25 0.039 3 GST-~CIT D816H ~ R634VIt0.08 0.04 2 C'aST-#~tT hl822H 0.37 0.12 5 t;ST-r'~IT N822K 0.15 0,058 5 .,r".,ST-~CiT Y823D ~ 0.13 0.0075 3 ASSay cOnditiOnS: 1 NM ATP, 5 Ng I ml Poly-EY, 10 min incubation at ambient temperature Virus containing media was collected from the transfected cell culture and used for infection to increase its titer. Virus containing media obtained after two rounds of infection was used for large-scale protein expression. For large-scale protein expression 100 cm2 round tissue culture plates were seeded with 5 x 10' cells/plate and infected with 1 mL of virus-containing media (approximately 5 MOIs). After 3 days, the cells were scraped off the plate and centrifuged at 500 rpm for 5 minutes. Cell pellets from 10-20, 100 cm2 plates, were re-suspended in 50 mL of ice-cold lysis buffer (25 mM Tris-HCI, pH 7.5, 2 mM EDTA, 1 % NP-40, 1 mM DTT, 1 mM PMSF). The cells were stirred on ice for 15 minutes and then centrifuged at 5000 rpm for 20 minutes.
The centrifuged cell lysate was loaded onto a 2 mL glutathione-sepharose column (Pharmacia) and washed 3 x with 10 mL of 25 mM Tris-HCI, pH 7.5, 2 mM EDTA, 1 mM
DTT, 200 mM NaCI. The GST-tagged proteins were then eluted by 10 applications (1 mL
each) of 25 mM Tris-HCI, pH 7.5, 10 mM reduced-glutathione, 100 mM NaCI, 1 mM
DTT, 10% glycerol and stored at -70°C.
The protein kinase activities of the various Kit mutants 200-500 ng were assayed in the presence or absence of inhibitors, 20 mM Tris-HCI, pH 7.6, 3 mM MnCl2, 3 mM MgCh, 1 mM DTT, 10 pM Na3V04, 3 pg/mL poly(GIu,Tyr) 4:1, 1% DMSO, 1.5 ~rM ATP (y-[33P]-ATP
0.1 pCi). The assay (30 pL) was carried out in 96-well plates at ambient temperature for 30 minutes and the reaction terminated by the addition of 20 pL of 125 mM
EDTA.
Subsequently, 30 pl of the reaction mixture were transferred onto Immobilon-PVDF
membrane (Millipore, Bedford, MA, USA) previously soaked for 5 minutes with methanol, rinsed with water, then soaked for 5 minutes with 0.5% H3P04 and mounted on vacuum manifold with disconnected vacuum source. After spotting all samples, vacuum was connected and each well rinsed with 200 pL 0.5% H3P04. Membranes were removed and washed 4 x on a shaker with 1.0% H3PO4, once with ethanol. Membranes were counted after drying at ambient temperature, mounting in Packard TopCount 96-well frame, and addition of 10 pUwell of Microscint (Packard). ICSO values were calculated by linear regression analysis of the percentage inhibition of each compound in duplicate, at 4 concentrations (usually 0.01, 0.1, 1 and 10 pM). One unit of protein kinase activity is defined as 1 nmole of 33P transferred from [y33P]ATP to the substrate protein/minute/mg of protein at RT.
e~ouv(msy De( 550-558 + V654A
Tn7R............_.......
F.roRt(20i11 pFB-G01-c-IfIT ,1"tt(zosyN822K
6828 by ~ sart(zo;tl %' ' De1557-561 "
__sun (zosi7 -~~~-,smit2o9."> Dej550-558 ~' ~
,'':~~
1'nti(=IGi) , D816N
'.~;
\ aa(zlztl ~.Ynoit~t:6>
' prri (2132?
' ~A
' ; D816V
t~ui(?san ;' ~ttrn~uittnss ,' Tn7L
AmpR
I ' De1557-561+V654 A
Figure 1 Vatalanib Compound A
Kit Mutation ICso (pM) (avg) ICSO (wM) (avg) D816F >10 >10 D816H >10 >10 D816N >10 <10 D816Y >10 >10 D816V >10 >10 K642E <1 <10 Y823D <1 <1 Del 550-558 <1 <2 Del 557-561 <1 <2 N822K <2 <10 V654A >10 >10 N822H <2 <10 Del 550-558 + <10 <10 Del 557-561 + >10 >10 Midostaurin average N of HIS pre aration IC50 SEM values M
HT-KtT-TA23 art 1.7 0.15 2 HT-KiT TA23 -D820t~ 0.084 0.05 2 HT-tCIT TA23 -T6701 0.89 0.21 2 average N of CAST preparation IC50 SEM values ~M
t~3T-KIT ~,tt 1.8 0.26 10 #;~ST-#~I"f Del 557-561 0.32 0.042 3 CST-f~IT Del 550-558 0.53 0.057 3 CST-ESIT l3el 550-55$x- 0.27 0.079 5 CST-IaCIT Del 557-561 0.34 0.11 5 ~- ~~aS~.A
O xT-I'IT ~'G54A 0.46 0.16 5 t,~ST-fCIT I~642E 0.64 0.036 4 ~aST-fCIT I~tG34~! 0.33 0.13 2 t~ST-~fi#T T6701 + ~e1 0.11 0.05 2 ~ST-~GIT' t581t~P 0.41 0.055 5 SST-I'CIT D816H 0.35 0.078 5 GST-I~CIT D816~1 0.74 0.25 5 ~'aST-i~IT i~Sl6Y 0.29 0.11 9 SST-k~IT #~816'~T 0.25 0.039 3 GST-~CIT D816H ~ R634VIt0.08 0.04 2 C'aST-#~tT hl822H 0.37 0.12 5 t;ST-r'~IT N822K 0.15 0,058 5 .,r".,ST-~CiT Y823D ~ 0.13 0.0075 3 ASSay cOnditiOnS: 1 NM ATP, 5 Ng I ml Poly-EY, 10 min incubation at ambient temperature Virus containing media was collected from the transfected cell culture and used for infection to increase its titer. Virus containing media obtained after two rounds of infection was used for large-scale protein expression. For large-scale protein expression 100 cm2 round tissue culture plates were seeded with 5 x 10' cells/plate and infected with 1 mL of virus-containing media (approximately 5 MOIs). After 3 days, the cells were scraped off the plate and centrifuged at 500 rpm for 5 minutes. Cell pellets from 10-20, 100 cm2 plates, were re-suspended in 50 mL of ice-cold lysis buffer (25 mM Tris-HCI, pH 7.5, 2 mM EDTA, 1 % NP-40, 1 mM DTT, 1 mM PMSF). The cells were stirred on ice for 15 minutes and then centrifuged at 5000 rpm for 20 minutes.
The centrifuged cell lysate was loaded onto a 2 mL glutathione-sepharose column (Pharmacia) and washed 3 x with 10 mL of 25 mM Tris-HCI, pH 7.5, 2 mM EDTA, 1 mM
DTT, 200 mM NaCI. The GST-tagged proteins were then eluted by 10 applications (1 mL
each) of 25 mM Tris-HCI, pH 7.5, 10 mM reduced-glutathione, 100 mM NaCI, 1 mM
DTT, 10% glycerol and stored at -70°C.
The protein kinase activities of the various Kit mutants 200-500 ng were assayed in the presence or absence of inhibitors, 20 mM Tris-HCI, pH 7.6, 3 mM MnCl2, 3 mM MgCh, 1 mM DTT, 10 pM Na3V04, 3 pg/mL poly(GIu,Tyr) 4:1, 1% DMSO, 1.5 ~rM ATP (y-[33P]-ATP
0.1 pCi). The assay (30 pL) was carried out in 96-well plates at ambient temperature for 30 minutes and the reaction terminated by the addition of 20 pL of 125 mM
EDTA.
Subsequently, 30 pl of the reaction mixture were transferred onto Immobilon-PVDF
membrane (Millipore, Bedford, MA, USA) previously soaked for 5 minutes with methanol, rinsed with water, then soaked for 5 minutes with 0.5% H3P04 and mounted on vacuum manifold with disconnected vacuum source. After spotting all samples, vacuum was connected and each well rinsed with 200 pL 0.5% H3P04. Membranes were removed and washed 4 x on a shaker with 1.0% H3PO4, once with ethanol. Membranes were counted after drying at ambient temperature, mounting in Packard TopCount 96-well frame, and addition of 10 pUwell of Microscint (Packard). ICSO values were calculated by linear regression analysis of the percentage inhibition of each compound in duplicate, at 4 concentrations (usually 0.01, 0.1, 1 and 10 pM). One unit of protein kinase activity is defined as 1 nmole of 33P transferred from [y33P]ATP to the substrate protein/minute/mg of protein at RT.
Claims (26)
1. A method of treating a KIT dependent disease in a patient, which comprises:
(a) identifying a mutant form of KIT associated with the KIT dependent disease; and (b) administering to said patient an effective mutant KIT inhibiting amount of an inhibitor selected from the group consisting of midostaurin, vatalanib and compound A.
(a) identifying a mutant form of KIT associated with the KIT dependent disease; and (b) administering to said patient an effective mutant KIT inhibiting amount of an inhibitor selected from the group consisting of midostaurin, vatalanib and compound A.
2. A method of Claim 1, wherein the mutant form of KIT is selected from D816F, D816H, D816N, D816Y, D816V, K642E, Y823D, Del 550-558, Del 557-561, N822K, V654A, N822H, Del 550-558 + V654A, Del 557-561 + V654A, Ins503AY, V560G, 558NP, Del 558, Del W559-560, F522C, Del 579, R634W, K642E, T8011, C809G, D820Y, N822K, N822H, Y823D, Y823C and T6701.
3. A method of Claim 2, wherein the mutant form of KIT is selected from D816F, D816H, D816N, D816Y, D816V, K642E, Y823D, Del 550-558, Del 557-561, N822K, V654A, N822H, Del 550-558 + V654A, Del 557-561 + V654A.
4. A method of Claim 1, wherein the KIT dependent disease is resistant to treatment with imatinib.
5. A method of Claim 3, wherein the mutant form of KIT is D816F and the inhibitor is selected from the group consisting of midostaurin.
6. A method of Claim 3, wherein the mutant form of KIT is D816H and the inhibitor is selected from the group consisting of midostaurin.
7. A method of Claim 3, wherein the mutant form of KIT is D816N and the inhibitor is selected from the group consisting of midostaurin and compound A.
8. A method of Claim 3, wherein the mutant form of KIT is D816Y and the inhibitor is selected from the group consisting of midostaurin.
9. A method of Claim 3, wherein the mutant form of KIT is D816V and the inhibitor is selected from the group consisting of midostaurin.
10. A method of Claim 3, wherein the mutant form of KIT is K642E and the inhibitor is selected from the group consisting of midostaurin, vatalanib and compound A.
11. A method of Claim 3, wherein the mutant form of KIT is Y823D and the inhibitor is selected from the group consisting of midostaurin, vatalanib and compound A.
12. A method of Claim 3, wherein the mutant form of KIT is Del 550-558 and the inhibitor is selected from the group consisting of midostaurin, vatalanib and compound A.
13. A method of Claim 3, wherein the mutant form of KIT is Del 557-561 and the inhibitor is selected from the group consisting of midostaurin, vatalanib and compound A.
14. A method of Claim 3, wherein the mutant form of KIT is N822K and the inhibitor is selected from the group consisting of midostaurin, vatalanib and compound A.
15. A method of Claim 3, wherein the mutant form of KIT is V654A and the inhibitor is selected from the group consisting of midostaurin.
16. A method of Claim 3, wherein the mutant form of KIT is N822H and the inhibitor is selected from the group consisting of midostaurin, vatalanib and compound A.
17. A method of Claim 3, wherein the mutant form of KIT is Del 550-558 + V654A
and the inhibitor is selected from the group consisting of midostaurin, vatalanib and compound A.
and the inhibitor is selected from the group consisting of midostaurin, vatalanib and compound A.
18. A method of Claim 3, wherein the mutant form of KIT is Del 557-561 + V654A
and the inhibitor is selected from the group consisting of midostaurin.
and the inhibitor is selected from the group consisting of midostaurin.
19. A method of Claim 2, wherein the mutant form of KIT is selected from the group consisting of D816H, D816F, D816N and D816Y and the inhibitor is midostaurin.
20. A method of Claim 2, wherein the mutant form of KIT is selected from the group consisting of D816V, K642E, Y823D, Del550-558, Del 557-561, N822K, V654A, N822H, Del 550-558 + V654A, and Del 557-561 + V654A and the inhibitor is midostaurin.
21. A method of Claim 2, wherein the mutant form of KIT is selected from the group consisting of K642E, Y823D, Del 550-558, Del 557-561, N822K and N822H and the inhibitor is vatalanib.
22. A method of Claim 2, wherein the mutant form of KIT is selected from the group consisting of D816H, D816N, K642E, Y823D, Del 550-558, Del 557-561, N822K and and the inhibitor is compound A.
23. A method according to any of Claims 1-22, wherein the KIT dependent disease is selected from mast cell diseases, acute myelogenous leukemia, gastrointestinal stromal tumors, seminomas and dysgerminomas.
24. A method of Claim 4, wherein the inhibitor is midostaurin.
25. A method of Claim 4, wherein the inhibitor is vatalanib.
26. A method of Claim 4, wherein the inhibitor is compound A.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2807475A CA2807475A1 (en) | 2003-11-18 | 2004-11-17 | Inhibitors of the mutant form of kit |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52071403P | 2003-11-18 | 2003-11-18 | |
| US60/520,714 | 2003-11-18 | ||
| PCT/EP2004/013045 WO2005049032A1 (en) | 2003-11-18 | 2004-11-17 | Inhibitors of the mutant form of kit |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2807475A Division CA2807475A1 (en) | 2003-11-18 | 2004-11-17 | Inhibitors of the mutant form of kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2546189A1 true CA2546189A1 (en) | 2005-06-02 |
| CA2546189C CA2546189C (en) | 2013-04-23 |
Family
ID=34619508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2546189A Expired - Fee Related CA2546189C (en) | 2003-11-18 | 2004-11-17 | Inhibitors of the mutant form of kit |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US8017621B2 (en) |
| EP (2) | EP1686997B1 (en) |
| JP (3) | JP4762150B2 (en) |
| KR (1) | KR101153647B1 (en) |
| CN (3) | CN102274230B (en) |
| AT (1) | ATE428426T1 (en) |
| AU (1) | AU2004290902B2 (en) |
| BR (1) | BRPI0416680A (en) |
| CA (1) | CA2546189C (en) |
| CY (1) | CY1110354T1 (en) |
| DE (1) | DE602004020654D1 (en) |
| DK (1) | DK1686997T3 (en) |
| ES (1) | ES2324917T3 (en) |
| HK (1) | HK1093680A1 (en) |
| HR (1) | HRP20090390T1 (en) |
| IL (2) | IL175578A (en) |
| MA (1) | MA28176A1 (en) |
| MX (1) | MXPA06005598A (en) |
| NO (1) | NO20062694L (en) |
| NZ (1) | NZ547195A (en) |
| PL (1) | PL1686997T3 (en) |
| PT (1) | PT1686997E (en) |
| RU (2) | RU2405553C1 (en) |
| SG (1) | SG139747A1 (en) |
| SI (1) | SI1686997T1 (en) |
| TN (1) | TNSN06138A1 (en) |
| WO (1) | WO2005049032A1 (en) |
| ZA (1) | ZA200603905B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| ATE428426T1 (en) | 2003-11-18 | 2009-05-15 | Novartis Pharma Gmbh | INHIBITOR OF THE MUTANT FORM OF KIT |
| KR20070046906A (en) * | 2004-08-31 | 2007-05-03 | 노파르티스 아게 | Use of midostaurin for treating gastrointestinal stromal tumors |
| MX2007013741A (en) | 2005-05-02 | 2008-01-21 | Novartis Ag | Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis. |
| CN101160130B (en) | 2005-05-02 | 2010-12-29 | 诺瓦提斯公司 | Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome |
| GT200600315A (en) * | 2005-07-20 | 2007-03-19 | CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA | |
| BRPI0613863A2 (en) * | 2005-07-20 | 2011-02-15 | Peter Valent | compositions for treating systemic mastocytosis |
| PL1959957T3 (en) | 2005-12-06 | 2012-12-31 | Novartis Ag | Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis |
| WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5936821B2 (en) * | 2008-01-23 | 2016-06-22 | ノバルティス アーゲー | Methods for optimizing the treatment with proliferative diseases imatinib mediated by the tyrosine kinase receptor KIT |
| US9801880B2 (en) | 2013-12-02 | 2017-10-31 | Bergenbio As | Use of kinase inhibitors |
| CN106188028A (en) * | 2015-05-05 | 2016-12-07 | 天津国际生物医药联合研究院 | Containing oxadiazoles heterocycle compound and its preparation method and application |
| WO2018014520A1 (en) * | 2016-07-18 | 2018-01-25 | 嘉兴雅康博医学检验所有限公司 | Primers, probes and kit for use in detecting c-kit gene mutations |
| EP3806858A4 (en) | 2018-06-15 | 2022-03-09 | Handa Pharmaceuticals, Inc. | Kinase inhibitor salts and compositions thereof |
| US20220010382A1 (en) * | 2018-11-12 | 2022-01-13 | Blueprint Medicines Corporation | Avapritinib resistance of kit mutants |
| US20210308133A1 (en) * | 2020-04-06 | 2021-10-07 | The Board Of Regents Of The University Of Texas System | Methods and compositions for inhibiting muscle wasting |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW225528B (en) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5543520A (en) * | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
| US5612340A (en) | 1993-10-01 | 1997-03-18 | Ciba-Geigy Corporation | Pyrimidineamine derivatives and processes for the preparation thereof |
| NZ274978A (en) * | 1993-10-12 | 1998-04-27 | Du Pont Merck Pharma | 1n-alkyl-n-aryl pyrimidinamine derivatives and pharmaceutical compositions thereof |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US6815791B1 (en) * | 1997-02-10 | 2004-11-09 | Fillfactory | Buried, fully depletable, high fill factor photodiodes |
| CO4950519A1 (en) | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
| GB2325934A (en) | 1997-06-03 | 1998-12-09 | Polybiomed Ltd | Treating metal surfaces to enhance bio-compatibility and/or physical characteristics |
| AU7821398A (en) | 1997-06-06 | 1998-12-21 | Baylor College Of Medicine | The mast cell secretory machine as a target for anti-allergy drug development |
| US5874603A (en) | 1997-07-15 | 1999-02-23 | Gelest, Inc. | Branched higher alkylsilanes |
| CO4940418A1 (en) | 1997-07-18 | 2000-07-24 | Novartis Ag | MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE |
| ATE432078T1 (en) | 1997-11-13 | 2009-06-15 | Mowycal Lending Llc | SMALL PEPTIDES AND METHODS FOR TREATING ASTHMA AND INFLAMMATION |
| US20040157855A1 (en) * | 2001-04-05 | 2004-08-12 | Michael Heinrich | Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders |
| CA2452171A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| TWI315982B (en) | 2001-07-19 | 2009-10-21 | Novartis Ag | Combinations comprising epothilones and pharmaceutical uses thereof |
| US20050095237A1 (en) | 2001-12-11 | 2005-05-05 | Emtage Peter C. | Methods of therapy and diagnosis using targeting of cells that express P2Y10 |
| EP1483401A1 (en) | 2002-03-13 | 2004-12-08 | F.Hoffmann-La Roche Ag | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0223341D0 (en) * | 2002-10-08 | 2002-11-13 | Groningen Acad Ziekenhuis | Organic compounds |
| TWI324604B (en) | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
| JP2007505859A (en) * | 2003-09-19 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| ATE428426T1 (en) | 2003-11-18 | 2009-05-15 | Novartis Pharma Gmbh | INHIBITOR OF THE MUTANT FORM OF KIT |
| MX2007013741A (en) | 2005-05-02 | 2008-01-21 | Novartis Ag | Use of pyrimidylamimobenzamide derivatives for the treatment of systematic mastocytosis. |
| CN200998572Y (en) * | 2007-01-29 | 2008-01-02 | 深圳市龙岗区坪山宽富高尔夫器具厂 | Golf club head cover capable of carrying repair piece |
| JP5448036B2 (en) * | 2009-02-18 | 2014-03-19 | トヨタ自動車株式会社 | Method for producing carboxylic acid |
-
2004
- 2004-11-17 AT AT04818795T patent/ATE428426T1/en active
- 2004-11-17 CN CN201110222445.0A patent/CN102274230B/en active Active
- 2004-11-17 SI SI200431159T patent/SI1686997T1/en unknown
- 2004-11-17 CN CNA2004800338582A patent/CN1882344A/en active Pending
- 2004-11-17 KR KR1020067009584A patent/KR101153647B1/en not_active IP Right Cessation
- 2004-11-17 WO PCT/EP2004/013045 patent/WO2005049032A1/en active Application Filing
- 2004-11-17 DK DK04818795T patent/DK1686997T3/en active
- 2004-11-17 RU RU2009110449/15A patent/RU2405553C1/en not_active IP Right Cessation
- 2004-11-17 NZ NZ547195A patent/NZ547195A/en not_active IP Right Cessation
- 2004-11-17 PT PT04818795T patent/PT1686997E/en unknown
- 2004-11-17 EP EP04818795A patent/EP1686997B1/en active Active
- 2004-11-17 JP JP2006540309A patent/JP4762150B2/en active Active
- 2004-11-17 RU RU2006121447/14A patent/RU2362562C2/en not_active IP Right Cessation
- 2004-11-17 DE DE602004020654T patent/DE602004020654D1/en active Active
- 2004-11-17 AU AU2004290902A patent/AU2004290902B2/en not_active Ceased
- 2004-11-17 BR BRPI0416680-9A patent/BRPI0416680A/en not_active Application Discontinuation
- 2004-11-17 CA CA2546189A patent/CA2546189C/en not_active Expired - Fee Related
- 2004-11-17 MX MXPA06005598A patent/MXPA06005598A/en active IP Right Grant
- 2004-11-17 ES ES04818795T patent/ES2324917T3/en active Active
- 2004-11-17 EP EP08100447A patent/EP1917965A1/en not_active Withdrawn
- 2004-11-17 CN CN200910169040A patent/CN101693031A/en active Pending
- 2004-11-17 SG SG200800338-6A patent/SG139747A1/en unknown
- 2004-11-17 PL PL04818795T patent/PL1686997T3/en unknown
- 2004-11-17 US US10/579,586 patent/US8017621B2/en active Active
-
2006
- 2006-05-11 IL IL175578A patent/IL175578A/en not_active IP Right Cessation
- 2006-05-15 TN TNP2006000138A patent/TNSN06138A1/en unknown
- 2006-05-16 ZA ZA200603905A patent/ZA200603905B/en unknown
- 2006-05-24 MA MA29054A patent/MA28176A1/en unknown
- 2006-06-12 NO NO20062694A patent/NO20062694L/en not_active Application Discontinuation
-
2007
- 2007-01-04 HK HK07100148.4A patent/HK1093680A1/en not_active IP Right Cessation
-
2009
- 2009-07-08 HR HR20090390T patent/HRP20090390T1/en unknown
- 2009-07-14 CY CY20091100748T patent/CY1110354T1/en unknown
-
2010
- 2010-02-04 US US12/700,106 patent/US8124611B2/en active Active
-
2011
- 2011-02-02 JP JP2011020873A patent/JP2011121973A/en active Pending
-
2012
- 2012-01-25 US US13/357,972 patent/US20120157441A1/en not_active Abandoned
-
2013
- 2013-07-22 JP JP2013151605A patent/JP2013241438A/en active Pending
- 2013-10-28 IL IL229124A patent/IL229124A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8124611B2 (en) | Inhibitors of the mutant form of kit | |
| US7098204B2 (en) | Hymenialdisine or derivatives thereof in the manufacture of medicaments | |
| MX2009000713A (en) | Jak inhibitors for treatment of myeloproliferative disorders. | |
| US8604045B2 (en) | Pyrimidylaminobenzamide derivatives for treatment of neurofibromatosis | |
| WO2002019213A2 (en) | Method for treatment of migraine using pde5 inhibitors | |
| KR20080004564A (en) | Pyrimidylaminobenzamide derivatives for hypereosinophilic syndrome | |
| CA2807475A1 (en) | Inhibitors of the mutant form of kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20191118 |